What is TLSI's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.25B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for TLSI?

P/E (TTM) is n/a and 52-week range is $2.20 to $7.95 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s TLSI figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for TLSI?

The company profile lists revenue (TTM) near $47M, net income (TTM) near $-2.97B, EPS (TTM) near $-0.59 when available from the market-data feed. Figures are informational and may lag live markets.

Where is TriSalus Life Sciences Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Westminster, Colorado, US, 61.4M shares outstanding, ISIN US89680M1018 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

TriSalus Life Sciences Inc

$TLSI

Health Care · Biotechnology

IR Run Scenarios

$4.06

-1.69%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

TriSalus Life Sciences, Inc. is an oncology company, which engages in the business of integrating standard-of-care treatments and investigational immunotherapeutic with disruptive pressure enabled drug delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. The company is headquartered in Westminster, Colorado and currently employs 102 full-time employees. The company went IPO on 2020-12-18. The company is seeking to transform outcomes for patients with solid tumors by integrating its delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technological applications. Its delivery method, Pressure-Enabled Drug Delivery (PEDD), modulates pressure and flow within blood vessels to improve intravascular therapeutic delivery into tumors, thereby increasing the likelihood of tumor response in comparison to conventional delivery technologies. Its on-market TriNav Infusion System using PEDD technology, is being used for interventional radiology procedures, commonly transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or in patients with liver metastases. TriNav is a device with a novel (PEDD) delivery method.

Employees

102

Website

trisaluslifesci.com/

IPO

2020-12-18

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)